Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688863 | 0.86 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3MCHR1CYP3A4 | |
| SCHEMBL13335114 | 0.86 | ESR2 (0.44) | SLC6A2SLC6A4SLC6A3MCHR1HTR2C | |
| SCHEMBL18027649 | 0.84 | ESR2 (0.44) | SLC6A2SLC6A4SLC6A3MCHR1CYP3A4 | |
| SCHEMBL16015355 | 0.84 | HAO1 (0.43) | SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL1688853 | 0.82 | SLC6A4 (0.42) | SLC6A2SLC6A4SLC6A3MCHR1HTR2C | |
| SCHEMBL4549740 | 0.78 | SLC18A3 (0.41) | — | |
| SCHEMBL3439658 | 0.78 | SYK (0.41) | SLC6A2SLC6A4SLC6A3MCHR1CYP2D6 | |
| SCHEMBL28452075 | 0.76 | SLC6A4 (0.45) | SLC6A4L3MBTL1LIPGAR | |
| SCHEMBL13308495 | 0.76 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3MCHR1 | |
| SCHEMBL446449 | 0.75 | AR (0.47) | SLC6A4L3MBTL1LIPGAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901353-B2 | Polyimide precursor, polyimide, and liquid crystal aligning agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8829153-B2 | Polyimide precursor composition containing polyamic acid alkyl ester | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120101236-A1 | POLYIMIDE PRECURSOR COMPOSITION CONTAINING POLYAMIC ACID ALKYL ESTER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | PUF60, F13A1, F12 | SLC6A2 3734/4885SLC6A4 4287/4885SLC6A3 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.